Retrophin announced that the first patient has been dosed in the PROTECT study, a global, pivotal Phase 3 clinical trial evaluating the long-term nephroprotective potential of sparsentan for the treatment of IgA nephropathy, a rare kidney disorder that often leads to end-stage renal disease.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.